Replimune (NASDAQ:REPL) stock surges as Cantor Fitzgerald upgrades, citing improved odds for approval of its lead drug after an FDA exec change.
https://seekingalpha.com/news/4474689-replimune-stock-rises-cantor-fitzgerald-upgrades
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.